These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 25319731)

  • 21. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C.
    Marcellin P; Forns X; Goeser T; Ferenci P; Nevens F; Carosi G; Drenth JP; Serfaty L; De Backer K; Van Heeswijk R; Luo D; Picchio G; Beumont M
    Gastroenterology; 2011 Feb; 140(2):459-468.e1; quiz e14. PubMed ID: 21034744
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-invasive fibrosis assessment predicts sustained virological response to telaprevir with pegylated interferon and ribavirin for chronic hepatitis C.
    Ogawa E; Furusyo N; Shimizu M; Ihara T; Hayashi T; Harada Y; Toyoda K; Murata M; Hayashi J
    Antivir Ther; 2015; 20(2):185-92. PubMed ID: 24941012
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of pretreatment serum interferon gamma inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C.
    Diago M; Castellano G; García-Samaniego J; Pérez C; Fernández I; Romero M; Iacono OL; García-Monzón C
    Gut; 2006 Mar; 55(3):374-9. PubMed ID: 16150856
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Amino acid substitutions in the hepatitis C virus core region of genotype 1b affect very early viral dynamics during treatment with telaprevir, peginterferon, and ribavirin.
    Akuta N; Suzuki F; Hirakawa M; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2010 Apr; 82(4):575-82. PubMed ID: 20166188
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationship of interferon-γ-inducible protein-10 kDa with viral response in patients with various heterogeneities of hepatitis C virus genotype-4.
    Al-Ashgar HI; Khan MQ; Helmy A; Al-Thawadi S; Al-Ahdal MN; Khalaf N; Al-Qahtani A; Sanai FM
    Eur J Gastroenterol Hepatol; 2013 Apr; 25(4):404-10. PubMed ID: 23470264
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin ± amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial.
    Pessôa MG; Cheinquer H; Almeida PR; Silva GF; Lima MP; Paraná R; Lacerda MA; Parise ER; Pernambuco JR; Pedrosa SS; Teixeira R; Sette H; Tatsch F
    Ann Hepatol; 2012; 11(1):52-61. PubMed ID: 22166561
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Telaprevir user's guide.
    Liapakis AM; Jacobson I
    Liver Int; 2012 Feb; 32 Suppl 1():17-25. PubMed ID: 22212567
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and efficacy of triple therapy with peginterferon, ribavirin and boceprevir within an early access programme in Spanish patients with hepatitis C genotype 1 with severe fibrosis: SVRw12 analysis.
    Calleja JL; Pascasio JM; Ruiz-Antorán B; Gea F; Bárcena R; Larrubia JR; Pérez-Álvarez R; Sousa JM; Romero-Gómez M; Solá R; de la Revilla J; Crespo J; Navarro JM; Arenas JI; Delgado M; Fernández-Rodríguez CM; Planas R; Buti M; Forns X;
    Liver Int; 2015 Jan; 35(1):90-100. PubMed ID: 25113158
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Amino acid substitution in the core protein has no impact on relapse in hepatitis C genotype 1 patients treated with peginterferon and ribavirin.
    Inoue Y; Hiramatsu N; Oze T; Yakushijin T; Mochizuki K; Fukuda K; Mita E; Haruna Y; Inoue A; Imai Y; Hosui A; Miyagi T; Yoshida Y; Tatsumi T; Kiso S; Kanto T; Kasahara A; Takehara T; Hayashi N
    J Med Virol; 2011 Mar; 83(3):419-27. PubMed ID: 21264862
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Telaprevir with peginterferon/ribavirin for retreatment of null responders with advanced fibrosis post-orthotopic liver transplant.
    Kwo PY; Ghabril M; Lacerda MA; Joseph Tector A; Fridell JA; Vianna R
    Clin Transplant; 2014 Jun; 28(6):722-7. PubMed ID: 24708229
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy.
    Harrison SA; Rossaro L; Hu KQ; Patel K; Tillmann H; Dhaliwal S; Torres DM; Koury K; Goteti VS; Noviello S; Brass CA; Albrecht JK; McHutchison JG; Sulkowski MS
    Hepatology; 2010 Sep; 52(3):864-74. PubMed ID: 20568303
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Telaprevir for previously untreated chronic hepatitis C virus infection.
    Jacobson IM; McHutchison JG; Dusheiko G; Di Bisceglie AM; Reddy KR; Bzowej NH; Marcellin P; Muir AJ; Ferenci P; Flisiak R; George J; Rizzetto M; Shouval D; Sola R; Terg RA; Yoshida EM; Adda N; Bengtsson L; Sankoh AJ; Kieffer TL; George S; Kauffman RS; Zeuzem S;
    N Engl J Med; 2011 Jun; 364(25):2405-16. PubMed ID: 21696307
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Triple therapy with telaprevir: results in hepatitis C virus-genotype 1 infected relapsers and non-responders.
    Forestier N; Zeuzem S
    Liver Int; 2012 Feb; 32 Suppl 1():44-50. PubMed ID: 22212571
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
    Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
    AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Telaprevir for previously treated chronic HCV infection.
    McHutchison JG; Manns MP; Muir AJ; Terrault NA; Jacobson IM; Afdhal NH; Heathcote EJ; Zeuzem S; Reesink HW; Garg J; Bsharat M; George S; Kauffman RS; Adda N; Di Bisceglie AM;
    N Engl J Med; 2010 Apr; 362(14):1292-303. PubMed ID: 20375406
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Health-related quality of life in genotype 1 treatment-naïve chronic hepatitis C patients receiving telaprevir combination treatment in the ADVANCE study.
    Vera-Llonch M; Martin M; Aggarwal J; Donepudi M; Bayliss M; Goss T; Younossi Z
    Aliment Pharmacol Ther; 2013 Jul; 38(2):124-33. PubMed ID: 23725204
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sustained virological response with telaprevir in 1,078 patients with advanced hepatitis C: the international telaprevir access program.
    Colombo M; Strasser S; Moreno C; Abrao Ferreira P; Urbanek P; Fernández I; Abdurakmonov D; Streinu-Cercel A; Verheyen A; Iraqi W; DeMasi R; Hill A; Lonjon-Domanec I; Wedemeyer H
    J Hepatol; 2014 Nov; 61(5):976-83. PubMed ID: 24946280
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of early null response to pegylated interferon and ribavirin as a predictor of therapeutic nonresponse in patients undergoing treatment for chronic hepatitis C.
    Reau N; Satoskar R; Te H; DeVoss A; Elsen C; Reddy G; Mohanty S; Jensen D
    Am J Gastroenterol; 2011 Mar; 106(3):452-8. PubMed ID: 21063395
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa-2a/ribavirin.
    Zeuzem S; Rodríguez-Torres M; Rajender Reddy K; Marcellin P; Diago M; Craxi A; Pockros P; Rizzetto M; Bernstein D; Shiffman ML; Lin A; Tatsch F; Hadziyannis S
    J Viral Hepat; 2012 Nov; 19(11):766-74. PubMed ID: 23043383
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.